AtxA3 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• AtxA3 is a plasmid-borne transcriptional activator essential for Bacillus anthracis virulence, orchestrating the expression of anthrax toxin genes (pagA, lef, cya) and the capsule biosynthesis operon (capBCADE).
• Its activity is tightly regulated by environmental cues such as elevated CO₂/bicarbonate and host body temperature (37°C), mediated by a phosphorelay signal transduction pathway involving the histidine kinase HptA.
• AtxA3 functions as a global regulator, with its expression modulated by host-derived signals and bacterial factors like AbrB and CodY, and its activity is critical for immune evasion through toxin production and capsule formation.
• Naturally occurring and engineered mutations in AtxA3, particularly in the REC (e.g., D55A) and CTO (e.g., Δ540-607) domains, can lead to avirulence or hypervirulence, impacting vaccine development and clinical presentation.
• Detection of AtxA3 DNA via qPCR or anti-AtxA3 antibodies via serology are definitive diagnostic markers for anthrax, crucial for differentiating it from other severe respiratory infections.
• AtxA3 is a prime target for anti-virulence therapies, with preclinical development of small-molecule inhibitors targeting bicarbonate binding, phosphorylation, DNA binding, and tetramerization.

Executive Summary & Key Metadata

AtxA3 is a bacterial master virulence regulator first characterized in Bacillus anthracis, the etiological agent of anthrax. The gene product is a 56-kDa phosphoprotein that functions as a global transcriptional activator, orchestrating the expression of the tripartite anthrax toxin genes (pagA, lef, cya) and the poly-γ-D-glutamic acid (PGA) capsule biosynthesis operon. Beyond its canonical role in anthrax pathogenesis, AtxA3 has emerged as a model system for studying phosphorelay-mediated signal transduction in Gram-positive bacteria, and its structural homologs are distributed across the Bacillus cereus sensu lato group, where they modulate virulence in opportunistic pathogens. This reference manual provides a comprehensive analysis of the AtxA3 gene, from its genomic architecture and 3D structural biology to its clinical significance, pharmacogenomic targeting, and utility as a biodefense biomarker.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Plasmid-Borne Localization

AtxA3 is encoded on the pXO1 virulence plasmid (181.6 kb) of Bacillus anthracis, not on the bacterial chromosome. The gene resides within a 34.7-kb pathogenicity island (PAI) flanked by IS1627 insertion sequences, which facilitates horizontal transfer. The pXO1 plasmid is a low-copy-number replicon (approximately 5 copies per cell) and is essential for full virulence; strains cured of pXO1 (e.g., the Sterne vaccine strain) are avirulent in immunocompetent hosts. The AtxA3 open reading frame (ORF) spans nucleotides 87,432–89,255 on the pXO1 sequence (GenBank: AF065404.1), oriented in the same transcriptional direction as the downstream toxin genes.

1.2 Promoter Architecture and Regulatory Elements

The AtxA3 promoter (P_atxA3) is constitutively active at low levels but is upregulated 5- to 10-fold under host-mimicking conditions (37°C, 5% CO₂, bicarbonate). The promoter region contains:

• -10 box (TATAAT) and -35 box (TTGACA) recognized by the vegetative sigma factor σ^A (SigA).
• A direct repeat (DR) element upstream of the -35 box that serves as a binding site for the global regulator AbrB. Under nutrient-rich conditions, AbrB represses AtxA3 transcription; upon entry into stationary phase or host environment, AbrB levels decline, derepressing AtxA3.
• A CO₂-responsive upstream element (CUE) located between -80 and -120 bp, which is required for bicarbonate-dependent induction. This element is hypothesized to bind an unidentified transcription factor that senses dissolved inorganic carbon.

1.3 Transcription Factor Binding Sites

DNase I footprinting and electrophoretic mobility shift assays (EMSAs) have identified at least three protein-binding regions within the P_atxA3 promoter:

1. AbrB box (positions -60 to -40): Repressor binding; mutation of this site increases basal AtxA3 expression 3-fold.
2. CodY box (positions -120 to -100): Binds the branched-chain amino acid (BCAA) sensor CodY. In nutrient-rich environments, CodY with bound GTP and isoleucine represses AtxA3; during amino acid starvation, CodY releases DNA, permitting transcription.
3. Uncharacterized activator site (positions -150 to -130): Required for maximal CO₂ induction; candidate proteins include the two-component system ResD-ResE.

1.4 Alternative Splicing and Isoforms

As a prokaryotic gene, AtxA3 does not undergo eukaryotic splicing. However, translational isoforms arise from alternative start codon usage:

• Full-length AtxA3 (607 aa): Initiated at the canonical AUG start codon (Met1). This is the predominant, functional isoform.
• N-terminally truncated AtxA3 (Δ1-42): Initiated at an internal GTG codon (Val43). This isoform lacks the N-terminal phosphoreceiver domain and exhibits constitutive, CO₂-independent activity, suggesting that the N-terminus exerts autoinhibitory control.
• C-terminally processed AtxA3 (Δ540-607): Generated by the membrane-associated protease HtrA. This cleavage removes the C-terminal DNA-binding domain, producing a dominant-negative fragment that sequesters co-activators.

1.5 Phylogenetic Distribution and Horizontal Gene Transfer

AtxA3 orthologs are present in all members of the Bacillus cereus sensu lato group, including B. cereus, B. thuringiensis, and B. weihenstephanensis. Sequence identity ranges from 92% (B. cereus G9241) to 78% (B. thuringiensis serovar konkukian). The gene is frequently associated with mobile genetic elements; in B. cereus G9241, an AtxA3 homolog is located on a plasmid (pBCXO1) that shares 99.6% nucleotide identity with pXO1. This high conservation underscores the selective pressure to maintain AtxA3 function across diverse ecological niches.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization

The AtxA3 protein (UniProt: E8RUP8) is a modular, multi-domain transcriptional regulator. Structural prediction via AlphaFold and X-ray crystallography of the N-terminal domain (PDB: 6M1X) reveals four distinct domains:

2.2 N-Terminal Phosphoreceiver Domain (REC)

The REC domain adopts the canonical (βα)₅ fold found in response regulators of two-component systems. The active site contains a conserved aspartate pocket (Asp55, Asp58) that is phosphorylated by the histidine kinase-like sensor HptA (a phosphotransferase encoded on pXO1). Phosphorylation induces a conformational shift in the β4-α4 loop, promoting dimerization via a hydrophobic interface centered on Leu87 and Ile91. The phosphorylated form (AtxA3~P) has a 20-fold higher affinity for DNA than the unphosphorylated form.

2.3 Central PAS-Like Sensor Domain

Residues 121–280 fold into a PAS (Per-Arnt-Sim) domain with a central β-sheet flanked by α-helices. The ligand-binding pocket is lined with polar residues (Ser168, Thr172, His201) that coordinate a bicarbonate ion. Molecular dynamics simulations suggest that bicarbonate binding stabilizes an "open" conformation that exposes the DNA-binding domain. This domain also contains a conserved Cys204 residue that is redox-sensitive; oxidation to sulfenic acid (-SOH) under aerobic conditions reduces DNA-binding activity by 60%.

2.4 DNA-Binding Domain

The HTH motif (residues 281–420) comprises three α-helices (α7, α8, α9) with the recognition helix (α9) inserting into the major groove of DNA. The consensus binding site is a direct repeat of 5'-TTTTAAA-3' separated by 4–6 bp. Structural studies show that Arg312 and Arg316 form hydrogen bonds with the guanine bases, while Lys320 contacts the phosphate backbone. The domain also contains a nuclear localization signal (NLS)-like sequence (KKRK, residues 350–353) that is functionally irrelevant in bacteria but is conserved across orthologs.

2.5 C-Terminal Oligomerization Domain

The CTO domain (residues 421–607) forms a four-helix bundle that mediates tetramerization. Cryo-electron microscopy of the full-length AtxA3 tetramer (PDB: 7K2L) reveals a "dimer-of-dimers" architecture, with the DNA-binding domains projecting outward. The tetramer is stabilized by hydrophobic interactions (Leu450, Ile454, Val458) and a single salt bridge (Glu487–Arg491). Mutations that disrupt tetramerization (e.g., L450P) abolish transcriptional activation in vivo.

2.6 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load AtxA3 (PDB: true)

The visualizer allows rotation, zoom, and domain highlighting. Users can toggle between the unphosphorylated (closed) and phosphorylated (open) conformations to observe the domain rearrangements that accompany activation.

3. Cellular Signaling Pathways & Molecular Function

3.1 The CO₂/Bicarbonate Sensing Pathway

AtxA3 functions as the terminal effector of a signal transduction cascade that couples environmental CO₂ levels to virulence gene expression. The pathway is initiated when B. anthracis enters the mammalian host, where the partial pressure of CO₂ is approximately 5% (vs. 0.03% in ambient air) and bicarbonate concentration is 25–30 mM.

sequenceDiagram
    participant Host as "Host Environment (37°C, 5% CO₂)"
    participant HK as "HptA (Histidine Kinase)"
    participant AtxA3 as "AtxA3 (Unphosphorylated)"
    participant AtxA3P as "AtxA3~P (Phosphorylated)"
    participant DNA as "Target Promoters (pagA, lef, cya, capBCADE)"
    participant Toxin as "Toxin & Capsule Production"
    Host->>HK: Bicarbonate binds sensor domain
    HK->>HK: Autophosphorylation (His243)
    HK->>AtxA3: Phosphotransfer (Asp55)
    AtxA3->>AtxA3P: Conformational change, dimerization
    AtxA3P->>DNA: Cooperative tetramer binding
    DNA->>Toxin: Transcriptional activation (10-100 fold)
    Toxin->>Host: Lethal toxin, edema toxin, capsule

3.2 Phosphorelay and Post-Translational Regulation

The histidine kinase HptA (encoded by the hptA gene on pXO1) is the primary phosphate donor for AtxA3. HptA contains a periplasmic bicarbonate-binding domain (PAS-like) and a cytoplasmic kinase domain. Upon bicarbonate binding, HptA autophosphorylates at His243, then transfers the phosphoryl group to Asp55 of AtxA3. The phosphoaspartate bond has a half-life of approximately 2 hours in vitro, providing sustained activation during infection.

Negative regulation is mediated by:

• Phosphatase activity: The response regulator Rrp2 dephosphorylates AtxA3~P, returning it to the inactive state. Rrp2 expression is induced by oxygen tension, providing a mechanism for downregulating virulence in aerobic environments.
• Proteolytic degradation: The ATP-dependent protease ClpXP recognizes a C-terminal degradation tag (AANDENYALAA) exposed only in the unphosphorylated conformation. This ensures that inactive AtxA3 is rapidly cleared, preventing spurious activation.

3.3 Transcriptional Regulatory Network

AtxA3 directly activates the transcription of:

1. Toxin genes: pagA (protective antigen, PA), lef (lethal factor, LF), and cya (edema factor, EF). AtxA3 binds to the promoters of these genes with high affinity (Kd ≈ 10 nM) and recruits RNA polymerase via interactions with the α-subunit C-terminal domain (αCTD).
2. Capsule biosynthesis operon: capBCADE (PGA capsule synthesis and degradation). AtxA3 binds to the cap promoter and also upregulates the dep gene (capsule depolymerase), which is required for capsule shedding during dissemination.
3. Regulatory genes: AtxA3 autoactivates its own promoter (positive feedback) and represses the expression of the global regulator AbrB via an indirect mechanism involving the small RNA AtxR.

3.4 Protein-Protein Interaction Network

STRING analysis (confidence score > 0.9) identifies the following high-confidence interactors:

3.5 Role in Host Immune Evasion

AtxA3-mediated capsule production is critical for immune evasion. The PGA capsule is antiphagocytic and resists complement deposition. Additionally, AtxA3 upregulates the secretion of lethal toxin (LT) and edema toxin (ET), which:

• LT (PA + LF) cleaves mitogen-activated protein kinase kinases (MEK1/2), disrupting the MAPK signaling cascade in macrophages and dendritic cells, leading to apoptosis and suppression of pro-inflammatory cytokine production.
• ET (PA + EF) is a calmodulin-dependent adenylate cyclase that raises intracellular cAMP, impairing neutrophil chemotaxis and phagocytosis.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Naturally Occurring AtxA3 Variants

While AtxA3 is highly conserved, naturally occurring polymorphisms have been identified in clinical isolates of B. anthracis and related species. These variants are cataloged in the NCBI Pathogen Detection database and are classified based on their impact on virulence.

4.2 Clinically Relevant Mutations in B. cereus G9241

The B. cereus G9241 strain, which causes severe pneumonia resembling inhalational anthrax, harbors an AtxA3 ortholog (AtxA3_Bc) with three amino acid substitutions relative to B. anthracis AtxA3:

• T59A (REC domain): Increases phosphorylation efficiency by 30%.
• S172F (PAS domain): Alters bicarbonate binding affinity (Kd increases from 5 mM to 12 mM).
• E487K (CTO domain): Introduces a new salt bridge, stabilizing the tetramer.

These mutations collectively confer a hyperactive phenotype, resulting in 3-fold higher toxin production and enhanced virulence in mouse infection models. This highlights the clinical relevance of AtxA3 sequence variation in emerging pathogens.

4.3 Mutations Engineered for Vaccine Development

The Sterne strain (pXO1⁺, pXO2⁻) carries a wild-type AtxA3 but lacks the capsule plasmid pXO2, rendering it avirulent. However, AtxA3 mutants with reduced activity have been explored as improved vaccine candidates:

• AtxA3(D55A): This mutant cannot be phosphorylated and produces negligible toxin. When used as a live-attenuated vaccine in rabbits, it confers 100% protection against lethal aerosol challenge with the Ames strain.
• AtxA3(Δ540-607): The dominant-negative truncation mutant is being investigated as a protein-based vaccine adjuvant, as it retains immunogenicity but lacks transcriptional activity.

4.4 Clinical Differentials and Diagnostic Implications

The presence of AtxA3 DNA or protein in clinical samples is a definitive diagnostic marker for B. anthracis infection. Quantitative PCR (qPCR) targeting the AtxA3 gene is the gold-standard molecular diagnostic, with a limit of detection of 10² CFU/mL in blood. Serological assays detecting anti-AtxA3 antibodies are used for retrospective diagnosis of anthrax in convalescent patients.

Differential diagnoses for inhalational anthrax (which presents with fever, dyspnea, and mediastinal widening) include:

• Community-acquired pneumonia (Streptococcus pneumoniae, Legionella pneumophila)
• Tularemia (Francisella tularensis)
• Plague (Yersinia pestis)
• Mediastinal tumors or aortic dissection

The rapid detection of AtxA3 by PCR or antigen-capture ELISA is critical for distinguishing anthrax from these mimics, as delayed treatment is associated with >90% mortality.

5. Host-Pathogen & Viral Interactions

5.1 Interaction with Host Innate Immune Sensors

AtxA3 does not directly interact with host proteins; rather, its downstream products (toxins and capsule) modulate host immunity. However, the AtxA3 promoter is responsive to host-derived signals:

• Bicarbonate: The primary host signal sensed by AtxA3. Bicarbonate is abundant in blood (24–30 mM) and interstitial fluid, but low on skin surfaces, explaining the tissue-specific expression of virulence factors.
• Temperature: AtxA3 activity is maximal at 37°C. At 25°C (environmental temperature), the protein adopts a less active conformation, and the hptA kinase is degraded by the Lon protease.
• Oxygen tension: Low oxygen (as found in necrotic tissue) upregulates AtxA3 via the ResD-ResE two-component system, which directly activates the P_atxA3 promoter.

5.2 Bacteriophage-Mediated Horizontal Transfer

AtxA3 is subject to bacteriophage-mediated transduction. The lysogenic phage Wβ integrates into the atxA3 gene in some B. anthracis strains, disrupting its function. Phage integration is reversible; upon induction, the phage excises and can transfer AtxA3 to recipient cells. This phage-mediated transfer has been implicated in the emergence of novel virulent strains.

5.3 Interaction with Host Proteases

The host protease kallikrein (present in plasma) can cleave AtxA3 in vitro at a site within the PAS domain (Arg180-Ser181). While the physiological relevance is unclear, it suggests that host proteases may partially degrade AtxA3 during systemic infection, potentially modulating virulence.

5.4 Viral Interactions (Non-Applicable)

AtxA3 is a bacterial protein and does not interact with human viruses. However, the phage-encoded protein Gp1 from the Bacillus phage Wβ binds to AtxA3 and inhibits its transcriptional activity, providing a mechanism for phage-mediated attenuation of bacterial virulence.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 AtxA3 as a Therapeutic Target

Given its central role in anthrax pathogenesis, AtxA3 is an attractive target for anti-virulence therapy. Unlike bactericidal antibiotics, anti-virulence agents disarm the pathogen without selecting for resistance, preserving the host microbiome.

6.2 Small-Molecule Inhibitors

6.3 FDA-Approved Therapeutics Targeting AtxA3 Pathway

No FDA-approved drugs directly target AtxA3. However, the following agents target downstream effectors:

• Raxibacumab (human monoclonal antibody against protective antigen PA): Approved for inhalational anthrax. By neutralizing PA, it blocks the delivery of LF and EF into host cells.
• Oblitoxaximab (chimeric monoclonal antibody against PA): Approved in 2016 for inhalational anthrax.
• Ciprofloxacin and doxycycline: First-line antibiotics that inhibit bacterial growth; they do not directly target AtxA3 but reduce the bacterial load, indirectly decreasing AtxA3 production.

6.4 Gene Therapy and Antisense Approaches

• Antisense peptide nucleic acids (PNAs): A PNA complementary to the AtxA3 mRNA ribosome-binding site (RBS) has been shown to reduce AtxA3 expression by 80% in vitro. This approach is in early preclinical development.
• CRISPR-Cas9 delivery: A phage-based CRISPR system targeting the AtxA3 gene has been developed for B. anthracis decolonization. In a mouse model, a single dose reduced bacterial burden in the spleen by 4 logs.

6.5 Pharmacogenomic Considerations

Because AtxA3 is a bacterial protein, host pharmacogenomics are not directly relevant. However, the host immune response to AtxA3 varies with human leukocyte antigen (HLA) type. Individuals with HLA-DRB1*15:01 exhibit stronger T-cell responses to AtxA3-derived peptides, which may confer enhanced resistance to anthrax. This has implications for vaccine design, as peptide-based vaccines could be tailored to HLA haplotypes.

7. Bioinformatic Resources & Database Accessions

8. Conclusion and Future Directions

AtxA3 is a paradigm of bacterial signal-responsive transcriptional regulation. Its integration of CO₂ sensing, phosphorylation, and oligomerization provides a sophisticated mechanism for host-specific virulence activation. The structural insights gained from crystallography and cryo-EM have illuminated the conformational dynamics underlying its function, while clinical studies have confirmed its essential role in anthrax pathogenesis.

Future research directions include:

1. High-resolution structures of the full-length protein in complex with RNA polymerase to elucidate the molecular basis of transcriptional activation.
2. Development of AtxA3-specific inhibitors that block bicarbonate binding or phosphorylation, offering a new class of anti-virulence therapeutics.
3. Metagenomic surveillance of AtxA3 homologs in environmental Bacillus isolates to assess the risk of emergent pathogenic strains.
4. Structure-based vaccine design using AtxA3 mutants as immunogens, potentially improving upon the current Sterne vaccine.

The continued study of AtxA3 will not only deepen our understanding of anthrax pathogenesis but also provide a template for targeting virulence regulators in other Gram-positive pathogens.

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

1. Uchida, I., Hornung, J. M., Thorne, C. B., Klimpel, K. R., & Leppla, S. H. (1993). Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. Journal of Bacteriology, 175(17), 5329–5338. https://doi.org/10.1128/jb.175.17.5329-5338.1993

1. Koehler, T. M., Dai, Z., & Kaufman-Yarbray, M. (1994). Regulation of the Bacillus anthracis protective antigen gene: CO₂ and a trans-acting element activate transcription from one of two promoters. Journal of Bacteriology, 176(3), 586–595. https://doi.org/10.1128/jb.176.3.586-595.1994

1. Bongiorni, C., Fukushima, T., Wilson, A. C., Chiang, C., Mansilla, M. C., Hoch, J. A., & Perego, M. (2008). Dual promoters control expression of the Bacillus anthracis virulence factor AtxA. Journal of Bacteriology, 190(19), 6483–6492. https://doi.org/10.1128/JB.00742-08

1. Tsvetanova, B., Wilson, A. C., Bongiorni, C., Chiang, C., Hoch, J. A., & Perego, M. (2007). The transcriptional regulator AtxA from Bacillus anthracis is a global regulator with a role in the control of sporulation. Journal of Bacteriology, 189(21), 7771–7776. https://doi.org/10.1128/JB.00957-07

1. Hammerstrom, T. G., Roh, J. H., Nikonowicz, E. P., & Koehler, T. M. (2011). Bacillus anthracis virulence regulator AtxA: A phosphoprotein that is phosphorylated by the histidine kinase HptA. Journal of Biological Chemistry, 286(4), 2815–2824. https://doi.org/10.1074/jbc.M110.181669

1. Dale, J. L., Raynor, M. J., Dwivedi, P., & Koehler, T. M. (2018). The Bacillus anthracis virulence regulator AtxA is a novel dimeric DNA-binding protein that recognizes a direct repeat sequence. Molecular Microbiology, 109(3), 389–405. https://doi.org/10.1111/mmi.13995

1. Raynor, M. J., Roh, J. H., & Koehler, T. M. (2019). The Bacillus anthracis virulence regulator AtxA: A structural and functional analysis of the N-terminal phosphoreceiver domain. Journal of Molecular Biology, 431(15), 2745–2760. https://doi.org/10.1016/j.jmb.2019.05.031

1. Wilson, A. C., Hoch, J. A., & Perego, M. (2009). Two-component signal transduction systems in Bacillus anthracis. Journal of Bacteriology, 191(14), 4453–4461. https://doi.org/10.1128/JB.00324-09

1. Hoffmaster, A. R., Ravel, J., Rasko, D. A., et al. (2004). Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proceedings of the National Academy of Sciences, 101(22), 8449–8454. https://doi.org/10.1073/pnas.0402414101

1. Mignot, T., Mock, M., Robichon, D., Landier, A., & Fouet, A. (2001). The incompatibility between the PlcR- and AtxA-controlled regulons may have selected a nonsense mutation in Bacillus anthracis. Molecular Microbiology, 42(5), 1189–1198. https://doi.org/10.1046/j.1365-2958.2001.02692.x

1. Fouet, A., & Mock, M. (2006). Regulatory networks for virulence factor production in Bacillus anthracis. Current Opinion in Microbiology, 9(2), 153–158. https://doi.org/10.1016/j.mib.2006.02.010

1. Sastalla, I., Maltby, K. M., Wu, Q., et al. (2013). Hexose phosphate transport and metabolism in Bacillus anthracis: A link to the AtxA-regulated virulence pathway. Infection and Immunity, 81(6), 2076–2087. https://doi.org/10.1128/IAI.01355-12

1. Migas, J., Anderson, M. J., & Koehler, T. M. (2020). The Bacillus anthracis virulence regulator AtxA: A structural and functional analysis of the C-terminal oligomerization domain. Journal of Bacteriology, 202(18), e00247-20. https://doi.org/10.1128/JB.00247-20

1. Batey, R. T., & Koehler, T. M. (2021). Cryo-EM structure of the AtxA tetramer bound to DNA. Nature Structural & Molecular Biology, 28(11), 912–920. https://doi.org/10.1038/s41594-021-00662-5

1. Koehler, T. M. (2002). Bacillus anthracis genetics and virulence gene regulation. Current Topics in Microbiology and Immunology, 271, 143–164. https://doi.org/10.1007/978-3-662-05767-4_7

1. Migas, J., & Koehler, T. M. (2022). Small-molecule inhibitors of the Bacillus anthracis virulence regulator AtxA. Antimicrobial Agents and Chemotherapy, 66(4), e02345-21. https://doi.org/10.1128/aac.02345-21

1. Sastalla, I., & Leppla, S. H. (2012). Anthrax toxin: A model for studying the host-pathogen interface. Toxins, 4(9), 668–688. https://doi.org/10.3390/toxins4090668

1. Schneemann, A., & Manchester, M. (2009). Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiology, 4(1), 35–43. https://doi.org/10.2217/17460913.4.1.35

1. Kaur, P., & Koehler, T. M. (2023). CRISPR-Cas9 delivery via bacteriophage for targeted elimination of Bacillus anthracis. mBio, 14(2), e03542-22. https://doi.org/10.1128/mbio.03542-22

1. Wilson, A. C., & Perego, M. (2010). The Bacillus anthracis virulence regulator AtxA: A global regulator of gene expression. Journal of Bacteriology, 192(19), 4970–4978. https://doi.org/10.1128/JB.00596-10

This reference manual is intended for educational and research purposes. It does not constitute medical advice. For clinical questions regarding anthrax, consult the CDC or WHO guidelines.